The guidelines of the European Association of Urology and National Comprehensive Cancer Network recommend BRCA1/2 testing for PCa patients with positive family history, high-risk or very high-risk localized or metastatic disease [6, 7]. The gene discussed is BRCA1; the disease is posterior cortical atrophy.